Objective: To investigate the effect of atosiban in the blood glucose levels of pregnant women and to examine how this change affects the newborn. Methods: The survey was conducted on 97 pregnant women who were hospitalized with preterm labor and administered Atosiban between January 2013 to December 2018. Maternal Fasting blood glucose and 2hours postprandial blood glucose were checked before and during the administration of Atosiban. Blood glucose levels measured during steroid administration were excluded from the study. We retrospectively investigated maternal and neonatal outcomes. Results: The mean random blood glucose level at the time of admission to the whole group was (88.6±19.8), whereas the mean Fasting blood glucose level after Atosiban administration was (111.2±16.4), which was increased by (22.6 ± 21.8) (P <0.001). Of the 111 newborns examined, 74 had neonatal hypoglycemia within 1 hour after birth requiring early feeding or IV glucose treatment, 14 of the 74 neonates had a level of less than 40 who needs immediate IV glucose treatment. Compared to pregnant women who showed an increase in blood glucose levels less than 20 mg/dL (58.1 ± 15.5, n=50) those who showed an increase in blood glucose levels over 20 mg/dL (50.1±14.1, n=46) showed significantly lower levels of neonatal blood glucose level (p=0.010). Conclusion: Atosiban can cause statistically significant maternal hyperglycemia during medication, which can cause neonatal hypoglycemia requiring treatment. It is necessary to monitor the neonatal hypoglycemia after birth in the case of atosiban-administered mothers during pregnancy.